Elvitegravir (Vitekta)

Published October 15, 2012; Updated June 06, 2018
Susa Coffey, MD
Selected Reference
7. Molina JM, LaMarca A, Andrade-Villanueva J, et al; Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27-35.